Compare CNK & ADMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CNK | ADMA |
|---|---|---|
| Founded | 1984 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3B | 3.6B |
| IPO Year | 2007 | 2012 |
| Metric | CNK | ADMA |
|---|---|---|
| Price | $29.17 | $9.17 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 2 |
| Target Price | ★ $32.90 | $32.00 |
| AVG Volume (30 Days) | 1.6M | ★ 8.5M |
| Earning Date | 05-01-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.23% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | 0.60 |
| Revenue | ★ $3,115,000,000.00 | $42,219,783.00 |
| Revenue This Year | $10.82 | $27.46 |
| Revenue Next Year | $3.68 | $22.11 |
| P/E Ratio | $28.09 | ★ $15.33 |
| Revenue Growth | 2.15 | ★ 43.85 |
| 52 Week Low | $21.60 | $7.21 |
| 52 Week High | $34.01 | $25.67 |
| Indicator | CNK | ADMA |
|---|---|---|
| Relative Strength Index (RSI) | 67.38 | 25.08 |
| Support Level | $24.88 | $7.21 |
| Resistance Level | $30.88 | $16.44 |
| Average True Range (ATR) | 0.99 | 1.13 |
| MACD | 0.15 | -0.43 |
| Stochastic Oscillator | 95.49 | 21.58 |
Cinemark Holdings Inc is a geographically diverse operator in the motion picture exhibition industry in the United States. The company generates revenue from filmed entertainment box office receipts and concession sales, with additional revenue from screen advertising, screen rentals, and other revenue streams, such as transactional fees, vendor marketing promotions, studio trailer placements, meeting rentals, and electronic video games located in some of the theatres. Cinemark manages its business under two reportable segments: U.S. markets and international markets. The majority of its revenue is generated from the U.S. markets segment.
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing, which generates maximum revenue, Plasma Collection Centres, and the corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling & packing services. The company derives maximum revenue from the United States.